Showing results (41-50 of 67) with videos related to

Sort By:
Pageof 7
Cancer Immunology, Immunotherapy : CII|February 25, 2026
A real-world comparison of nivolumab plus cabozantinib and pembrolizumab plus lenvatinib focusing on safety outcomes in metastatic renal cell carcinoma: results from the JK-FOOT consortiumTakafumi Yanagisawa, Keiichiro Mori, Tatsushi Kawada, et al.
International Journal of Clinical Oncology|September 5, 2025
Predictors of early progressive disease and antitumor effects by metastatic site in renal cell carcinoma treated with ipilimumab plus nivolumabKeiichiro Mori, Takafumi Yanagisawa, Tatsushi Kawada, et al.
Japanese Journal of Clinical Oncology|August 23, 2024
Clinical outcomes and prognostic factors in metastatic nonclear cell renal cell carcinoma treated with immuno-oncology combination therapyShingo Toyoda, Wataru Fukuokaya, Keiichiro Mori, et al.
Japanese Journal of Clinical Oncology|May 17, 2026
Development of a prognostic model for elderly patients with metastatic clear cell renal cell carcinoma treated with first-line immuno-oncology combination therapyShinya Watanabe, Yuto Matsushita, Yuya Oishi, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|November 1, 2023
Transplanting old organs promotes senescence in young recipientsJasper Iske, Maximilian J Roesel, Friederike Martin, et al.
Cancers|February 12, 2021
Early Prostate-Specific Antigen (PSA) Change at Four Weeks of the First-Line Treatment Using Abiraterone and Enzalutamide Could Predict Early/Primary Resistance in Metastatic Castration-Resistant Prostate CancerTaizo Uchimoto, Kazumasa Komura, Wataru Fukuokaya, et al.
Cancers|July 24, 2021
Risk Classification for Overall Survival by the Neutrophil-Lymphocyte Ratio and the Number of Metastatic Sites in Patients Treated with Pembrolizumab-A Multicenter Collaborative Study in JapanTaizo Uchimoto, Kazumasa Komura, Wataru Fukuokaya, et al.
Hemasphere|July 14, 2025
PRC2-mediated apoptosis evasion is a therapeutic target of MDS/AML harboring inv(3)/t(3;3) and monosomy 7Hiroyoshi Kunimoto, Ayaka Miura, Maiko Sagisaka, et al.
Cancer Science|September 27, 2023
Tertiary lymphoid structure and neutrophil-lymphocyte ratio coordinately predict outcome of pembrolizumabKazumasa Komura, Satoshi Tokushige, Mitsuaki Ishida, et al.
Frontiers in Oncology|March 16, 2026
Penile involvement associated with renal pelvic squamous cell carcinoma: a case report and mechanistic considerationsKotaro Masaki, Takuya Tsujino, Hiroyuki Okada, et al.
Pageof 7